Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas


Peripheral T cell lymphomas (PTCLs) are a heterogeneous and poorly understood group of non-Hodgkin lymphomas1,2. Here we combined whole-exome sequencing of 12 tumor-normal DNA pairs, RNA sequencing analysis and targeted deep sequencing to identify new genetic alterations in PTCL transformation. These analyses identified highly recurrent epigenetic factor mutations in TET2, DNMT3A and IDH2 as well as a new highly prevalent RHOA mutation encoding a p.Gly17Val alteration present in 22 of 35 (67%) angioimmunoblastic T cell lymphoma (AITL) samples and in 8 of 44 (18%) PTCL, not otherwise specified (PTCL-NOS) samples. Mechanistically, the RHOA Gly17Val protein interferes with RHOA signaling in biochemical and cellular assays, an effect potentially mediated by the sequestration of activated guanine-exchange factor (GEF) proteins. In addition, we describe new and recurrent, albeit less frequent, genetic defects including mutations in FYN, ATM, B2M and CD58 implicating SRC signaling, impaired DNA damage response and escape from immune surveillance mechanisms in the pathogenesis of PTCL.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: RHOA mutations in PTCL.
Figure 2: Functional characterization of the RHOA Gly17Val protein.
Figure 3: DNMT3A, TET2, IDH2, FYN, ATM, TET3, B2M and CD58 alterations in PTCL.
Figure 4: Structural modeling and functional characterization of the FYN mutations identified in PTCL.

Similar content being viewed by others

Accession codes


NCBI Reference Sequence

Protein Data Bank


  1. Armitage, J.O. The aggressive peripheral T-cell lymphomas: 2012 update on diagnosis, risk stratification, and management. Am. J. Hematol. 87, 511–519 (2012).

    Article  Google Scholar 

  2. Rüdiger, T. et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. Ann. Oncol. 13, 140–149 (2002).

    Article  Google Scholar 

  3. Schiller, M.R. Coupling receptor tyrosine kinases to Rho GTPases–GEFs what's the link. Cell. Signal. 18, 1834–1843 (2006).

    Article  CAS  Google Scholar 

  4. Bar-Sagi, D. & Hall, A. Ras and Rho GTPases: a family reunion. Cell 103, 227–238 (2000).

    Article  CAS  Google Scholar 

  5. Vega, F.M. & Ridley, A.J. Rho GTPases in cancer cell biology. FEBS Lett. 582, 2093–2101 (2008).

    Article  CAS  Google Scholar 

  6. Hanna, S. & El-Sibai, M. Signaling networks of Rho GTPases in cell motility. Cell. Signal. 25, 1955–1961 (2013).

    Article  CAS  Google Scholar 

  7. Hall, A. Rho family GTPases. Biochem. Soc. Trans. 40, 1378–1382 (2012).

    Article  CAS  Google Scholar 

  8. Longenecker, K. et al. Structure of a constitutively activated RhoA mutant (Q63L) at 1.55 Å resolution. Acta Crystallogr. D Biol. Crystallogr. 59, 876–880 (2003).

    Article  Google Scholar 

  9. Mayer, T., Meyer, M., Janning, A., Schiedel, A.C. & Barnekow, A. A mutant form of the rho protein can restore stress fibers and adhesion plaques in v-src transformed fibroblasts. Oncogene 18, 2117–2128 (1999).

    Article  CAS  Google Scholar 

  10. Zhang, S. et al. Rho family GTPases regulate p38 mitogen-activated protein kinase through the downstream mediator Pak1. J. Biol. Chem. 270, 23934–23936 (1995).

    Article  CAS  Google Scholar 

  11. Ghosh, P.M. et al. Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line. Oncogene 18, 4120–4130 (1999).

    Article  CAS  Google Scholar 

  12. Pan, Z.K. et al. Role of the Rho GTPase in bradykinin-stimulated nuclear factor–κB activation and IL-1β gene expression in cultured human epithelial cells. J. Immunol. 160, 3038–3045 (1998).

    CAS  PubMed  Google Scholar 

  13. Reid, T. et al. Rhotekin, a new putative target for Rho bearing homology to a serine/threonine kinase, PKN, and rhophilin in the rho-binding domain. J. Biol. Chem. 271, 13556–13560 (1996).

    Article  CAS  Google Scholar 

  14. García-Mata, R. et al. Analysis of activated GAPs and GEFs in cell lysates. Methods Enzymol. 406, 425–437 (2006).

    Article  Google Scholar 

  15. Couronné, L., Bastard, C. & Bernard, O.A. TET2 and DNMT3A mutations in human T-cell lymphoma. N. Engl. J. Med. 366, 95–96 (2012).

    Article  Google Scholar 

  16. Quivoron, C. et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 20, 25–38 (2011).

    Article  CAS  Google Scholar 

  17. Cairns, R.A. et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood 119, 1901–1903 (2012).

    Article  CAS  Google Scholar 

  18. Palacios, E.H. & Weiss, A. Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene 23, 7990–8000 (2004).

    Article  CAS  Google Scholar 

  19. McCormack, P.L. & Keam, S.J. Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome–positive acute lymphoblastic leukaemia. Drugs 71, 1771–1795 (2011).

    Article  CAS  Google Scholar 

  20. Harr, M.W. et al. Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia. Cell Death Differ. 17, 1381–1391 (2010).

    Article  CAS  Google Scholar 

  21. Widmann, C., Gerwins, P., Johnson, N.L., Jarpe, M.B. & Johnson, G.L. MEK kinase 1, a substrate for DEVD-directed caspases, is involved in genotoxin-induced apoptosis. Mol. Cell. Biol. 18, 2416–2429 (1998).

    Article  CAS  Google Scholar 

  22. Li, H. & Durbin, R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 26, 589–595 (2010).

    Article  Google Scholar 

  23. Langmead, B. & Salzberg, S.L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357–359 (2012).

    Article  CAS  Google Scholar 

  24. Schmitz, R. et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 490, 116–120 (2012).

    Article  CAS  Google Scholar 

  25. Maher, C.A. et al. Chimeric transcript discovery by paired-end transcriptome sequencing. Proc. Natl. Acad. Sci. USA 106, 12353–12358 (2009).

    Article  CAS  Google Scholar 

  26. McPherson, A. et al. deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data. PLoS Comput. Biol. 7, e1001138 (2011).

    Article  CAS  Google Scholar 

  27. Pettersen, E.F. et al. UCSF Chimera—a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605–1612 (2004).

    Article  CAS  Google Scholar 

  28. Altschul, S.F. et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25, 3389–3402 (1997).

    Article  CAS  Google Scholar 

  29. Roy, A., Kucukural, A. & Zhang, Y. I-TASSER: a unified platform for automated protein structure and function prediction. Nat. Protoc. 5, 725–738 (2010).

    Article  CAS  Google Scholar 

  30. Worth, C.L., Preissner, R. & Blundell, T.L. SDM—a server for predicting effects of mutations on protein stability and malfunction. Nucleic Acids Res. 39, W215–W222 (2011).

    Article  CAS  Google Scholar 

  31. Subauste, M.C. et al. Rho family proteins modulate rapid apoptosis induced by cytotoxic T lymphocytes and Fas. J. Biol. Chem. 275, 9725–9733 (2000).

    Article  CAS  Google Scholar 

  32. Mariotti, A. et al. EGF-R signaling through Fyn kinase disrupts the function of integrin α6β4 at hemidesmosomes: role in epithelial cell migration and carcinoma invasion. J. Cell Biol. 155, 447–458 (2001).

    Article  CAS  Google Scholar 

  33. Kamanova, J. et al. Adenylate cyclase toxin subverts phagocyte function by RhoA inhibition and unproductive ruffling. J. Immunol. 181, 5587–5597 (2008).

    Article  CAS  Google Scholar 

  34. Pallotta, M.T. et al. Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat. Immunol. 12, 870–878 (2011).

    Article  CAS  Google Scholar 

  35. Schenk, S. et al. Sirt1 enhances skeletal muscle insulin sensitivity in mice during caloric restriction. J. Clin. Invest. 121, 4281–4288 (2011).

    Article  CAS  Google Scholar 

  36. Wang, Q. et al. Thrombin and lysophosphatidic acid receptors utilize distinct rhoGEFs in prostate cancer cells. J. Biol. Chem. 279, 28831–28834 (2004).

    Article  CAS  Google Scholar 

Download references


We would like to thank V. Ribrag (Institut Gustave Roussy) for providing a PTCL sample and R. Parsons (Mount Sinai School of Medicine) for assistance in the setup of RHOA GTP-loading assays. This work was supported by a Leukemia and Lymphoma Society Translational Research Grant (A.A.F.), a Herbert Irving Comprehensive Cancer Center interprogrammatic pilot project grant (A.A.F. and R.R.), a US National Institutes of Health Ruth L. Kirschstein National Research Service Award (1F30CA174099 to J.E.H.), a grant from the Ligue Nationale Contre le Cancer (O.A.B.) and an Institut National du Cancer (INCa)/–Direction de l'Hospitalisation et de l'Organisation des soins (DHOS) translational research grant (O.A.B.). L.C. is funded by ITMO (Institut Multi-Organismes Cancer) and INCa. M.-Y.K. is funded by the Leukemia and Lymphoma Society. E.C. is supported by the Spanish Ministry of Science and Innovation (SAF2012-38432) and Institucio Catalana de Recerca i Estudis Avancats.

Author information

Authors and Affiliations



T.P. directed and supervised mutation analysis, performed functional assays and wrote the manuscript. L.C. performed validation and recurrence mutation analysis and functional assays. H.K. performed exome and RNA-seq mutation analysis. M.-Y.K. performed peptide binding assays. A.A.-I. analyzed Illumina deep sequencing amplicon sequencing data. A.P.-G. performed functional assays. Z.C. performed structure-function analysis and analyzed Illumina sequence data. F.A. performed RNA-seq mutation analysis and fusion oncogene identification. M.A. performed validation analysis of Illumina sequencing results. J.E.H. performed functional assays. X.J. performed functional assays. I.S.L. contributed clinical samples and supervised functional assays. C.N., M.B., C.B., G.B., M.A.P. and E.C. contributed clinical samples. O.A.B. designed the study, contributed samples and supervised research. R.R. directed and supervised the analysis of Illumina sequencing data. A.A.F. designed the study, directed and supervised research and wrote the manuscript.

Corresponding authors

Correspondence to Teresa Palomero, Raul Rabadan or Adolfo A Ferrando.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Text and Figures

Supplementary Figures 1 and 2 and Supplementary Tables 1, 2, 4 and 6–8 (PDF 918 kb)

Supplementary Tables 3, 5 and 9

Supplementary Tables 3, 5 and 9 (XLSX 69 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Palomero, T., Couronné, L., Khiabanian, H. et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet 46, 166–170 (2014).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing